Cardiovascular complications of multiple myeloma in the elderly

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar 17; 364(11):1046–1060. DOI: 10.1056/NEJMra1011442.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. [cited 2017 Nov 20]. Available from: https://seer.cancer.gov/index.html
   Google Scholar
• Pulte D, Jansen L, Castro FA, et al. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer. 2016 Jul 1;122(13):2031–2040.
   PubMed Web of Science ®Google Scholar
• Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016 Jan;91(1):81–83.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29–322.
   PubMed Web of Science ®Google Scholar
• Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008 Jul 1;26(19):3159–3165.
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Castro FA, et al. GEKID cancer survival working group. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol. 2015 Oct;171(2):189–196.
   Google Scholar
• Mulrooney DA, Nunnery SE, Armstrong GT, et al. Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma. Cancer. 2014 Nov 15;120(22):3536–3544.
   PubMed Web of Science ®Google Scholar
• Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015 Mar;20(2):155–162.
   PubMed Web of Science ®Google Scholar
• Merz AA, Cheng S. Sex differences in cardiovascular ageing. Heart. 2016 Jun 1;102(11):825–831.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005 May 1; 23(13):2900–2902.
   PubMed Web of Science ®Google Scholar
• Gupta A, Pandey A, Sethi S. Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma. Cardiovasc Toxicol. 2012 Jun;12(2):184–187.
   PubMed Web of Science ®Google Scholar
• Bockorny M, Chakravarty S, Schulman P, et al. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 2012;128(4):244–247.
   PubMed Web of Science ®Google Scholar
• Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol. 2008 Sep;88(2):219–222.
   PubMed Web of Science ®Google Scholar
• Enrico O, Gabriele B, Nadia C, et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol. 2007 Aug;138(3):396–397.
   PubMed Web of Science ®Google Scholar
• Herrmann J, Saguner AM, Versari D, et al. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res. 2007;101(9):865–874.
   PubMed Web of Science ®Google Scholar
• Herrmann J, Wohlert C, Saguner AM, et al. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail. 2013;15(6):614–623.
   PubMed Web of Science ®Google Scholar
• Danhof S, Schreder M, Rasche L, et al. Real-life experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016 Jul;97(1):25–32.
   PubMed Web of Science ®Google Scholar
• Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015 Jan;16(5):e272.
   Google Scholar
• Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 2014 Dec;4(14):915.
   Google Scholar
• Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014 Sep 2;64(9):938–945.
   PubMed Web of Science ®Google Scholar
• Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302–314.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168–175.
   PubMed Web of Science ®Google Scholar
• Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res. 1983;43:4467–4469.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 Nov;18(11):1639–1642.
   PubMed Web of Science ®Google Scholar
• Deng S, Yan T, Jendrny C, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014 Nov;18(14):842.
   Google Scholar
• January CT, Wann LS, Alpert JS, et al. American College of Cardiology/American Heart Association Task Force on practice guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1–76.
   PubMed Web of Science ®Google Scholar
• Shah N, Rochlani Y, Pothineni NV, et al. Burden of arrhythmias in patients with multiple myeloma. Int J Cardiol. 2016 Jan;15(203):305–306.
   Google Scholar
• Gilotra NA, Chow GV, Cingolani OH. Cardiac amyloidosis presenting with prolonged QT interval and recurrent polymorphic ventricular tachycardia. Tex Heart Inst J. 2013;40(2):193–195.
   PubMed Web of Science ®Google Scholar
• Seldin DC, Berk JL, Sam F, et al. Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment. Heart Fail Clin. 2011 Jul;7(3):385–393.
   PubMed Web of Science ®Google Scholar
• Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol. 2004 Apr 15;93(8):1052.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal AF after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant. 1998 May;21(10):1049–1053.
   PubMed Web of Science ®Google Scholar
• Hidalgo JD, Krone R, Rich MW, et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2004 Oct;34(7):615–619.
   PubMed Web of Science ®Google Scholar
• Singla A, Hogan WJ, Ansell SM, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2013 Aug;19(8):1233–1237.
   PubMed Web of Science ®Google Scholar
• Sureddi RK, Amani F, Hebbar P, et al. Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors. Ther Adv Cardiovasc Dis. 2012 Dec;6(6):229–236.
   PubMedGoogle Scholar
• Fatema K, Gertz MA, Barnes ME, et al. Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation. Am J Hematol. 2009;84:499.
   PubMed Web of Science ®Google Scholar
• Kaakeh Y, Overholser BR, Lopshire JC, et al. Drug-induced atrial fibrillation. Drugs. 2012 Aug 20;72(12):1617–1630.
   PubMed Web of Science ®Google Scholar
• Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34:356–359.
   PubMed Web of Science ®Google Scholar
• Mathur P, Paydak H, Thanendrarajan S, et al. Atrial fibrillation in hematologic malignancies, especially after autologous hematopoietic stem cell transplantation: review of risk factors, current management, and future directions. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):70–75.
   PubMed Web of Science ®Google Scholar
• Reardon M, Camm AJ. Atrial fibrillation in the elderly. Clin Cardiol. 1996 Oct;19(10):765–775.
   PubMed Web of Science ®Google Scholar
• Falk RH, Alexander KM, Liao R, et al. AL (Light-Chain) Cardiac Amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016 Sep 20; 68(12):1323–1341.
   PubMed Web of Science ®Google Scholar
• Longhi S, Quarta CC, Milandri A, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22(3):147–155.
   PubMed Web of Science ®Google Scholar
• Franchini M, Frattini F, Crestani S, et al. Bleeding complications in patients with hematologic malignancies. Semin Thromb Hemost. 2013 Feb;39(1):94–100.
   PubMed Web of Science ®Google Scholar
• Zöller B, Li X, Sundquist J, et al. Age- and gender-specific familial risks for venous thromboembolism: a nationwide epidemiological study based on hospitalizations in Sweden. Circulation. 2011 Aug 30;124(9):1012–1020.
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004 Aug 1;101(3):558–566.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016 Jan;15(6):e384.
   Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809–815.
   PubMed Web of Science ®Google Scholar
• Li W, Cornell RF, Lenihan D, et al. Cardiovascular complications of novel multiple myeloma treatments. Circulation. 2016 Mar 1;133(9):908–912.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20;32(6):587–600.
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228–236.
   PubMed Web of Science ®Google Scholar
• Nayak L, Shi H, Atkins GB, et al. The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2). Blood. 2014;123:3828–3831.
   PubMed Web of Science ®Google Scholar
• Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004 Feb 4;43(3):410–415.
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005 Sep 27;112(13):2047–2060.
   PubMed Web of Science ®Google Scholar
• White JA, Fine NM. Recent advances in cardiovascular imaging relevant to the management of patients with suspected cardiac amyloidosis. Curr Cardiol Rep. 2016 Aug;18(8):77.
   PubMed Web of Science ®Google Scholar
• Bhatti S, Watts E, Syed F, et al. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2016 Sep;17(9):970–977.
   PubMed Web of Science ®Google Scholar
• Foley PW, Hamilton MS, Leyva F. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2010 May;11(5):386–388.
   PubMed Web of Science ®Google Scholar
• Herman EH, Lipshultz SE, Rifai N, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998 Jan 15;58(2):195–197.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000 Aug;36(2):517–522.
   PubMed Web of Science ®Google Scholar
• Stevens PL, Lenihan DJ. Cardiotoxicity due to chemotherapy: the role of biomarkers. Curr Cardiol Rep. 2015 Jul;17(7):603.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751–3757.
   PubMed Web of Science ®Google Scholar
• Geisberg CA, Abdallah WM, Da Silva M, et al. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. J Card Fail. 2013 Jan;19(1):10–15.
   PubMed Web of Science ®Google Scholar
• Henri C, Heinonen T, Tardif JC. The role of biomarkers in decreasing risk of cardiac toxicity after cancer therapy. Biomark Cancer. 2016 May 23;8(Suppl 2):39–45.
   PubMedGoogle Scholar
• Horacek JM, Tichy M, Jebavy L, et al. Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation. Ann Oncol. 2007 Dec;18(12):2041.
   PubMed Web of Science ®Google Scholar
• Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 Mar 4;63(8):809–816.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Stankowski RV, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012 Jul;134(1):291–298.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Reece DE, Sanchorawala V, et al. Velcade Can2007 study group. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. Qjm. 2011 Nov;104(11):957–970.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1825–1833.
   PubMed Web of Science ®Google Scholar
• Gillinov AM, Bagiella E, Moskowitz AJ, et al. CTSN. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016 May 19;374(20):1911–1921.
   PubMed Web of Science ®Google Scholar
• Riber LP, Christensen TD, Pilegaard HK. Amiodarone is a cost-neutral way of preventing atrial fibrillation after surgery for lung cancer. Eur J Cardiothorac Surg. 2014 Jan;45(1):120–125.
   PubMed Web of Science ®Google Scholar
• Barbhaiya CR, Kumar S, Baldinger SH, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016 Feb;13(2):383–390.
   PubMed Web of Science ®Google Scholar
• Sharma N, Howlett J. Current state of cardiac amyloidosis. Curr Opin Cardiol. 2013 Mar;28(2):242–248.
   PubMed Web of Science ®Google Scholar
• Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014 Jan;11(1):158–162.
   PubMed Web of Science ®Google Scholar
• Proietti M, Nobili A, Raparelli V, et al. REPOSI investigators. Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clin Res Cardiol. 2016 Nov;105(11):912–920.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhai Z, Yang Y, et al. Long-term treatment with low-molecular-weight heparin prolonged the survival time for acute pulmonary embolism patients concurrent with malignancy: an observational analysis from a long-term follow-up study. Thromb Res. 2015 Apr;135(4):582–587.
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldán V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312–318.
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F, Fernández H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013 Jan;143(1):179–184.
   PubMed Web of Science ®Google Scholar
• Maes F, Dalleur O, Henrard S, et al. Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? Clin Interv Aging. 2014 Jul;15(9):1091–1099.
   Google Scholar
• O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015 Dec 7;36(46):3258–3264.
   PubMed Web of Science ®Google Scholar
• Van Dalen EC, Caron HM, Dickinson HO, et al. Cardioprotective interventions for cancer patient receiving anthracyclines. Cochrane Database Syst Rev. 2011 Jun;15(6):CD003917.
   Google Scholar
• Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006 Dec 5;48(11):2258–2262.
   PubMed Web of Science ®Google Scholar
• Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005 Dec 1;104(11):2492–2498.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 Dec 5;114(23):2474–2481.
   PubMed Web of Science ®Google Scholar
• Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013 Jun 11;61(23):2355–2362.
   PubMed Web of Science ®Google Scholar
• Raina S, Pant S, Vallurupalli S, et al. Can autologous bone marrow transplantation improve systolic function in patients with multiple myeloma related cardiac amyloidosis? Int J Cardiol. 2014 Mar 1;172(1):265–266.
   PubMed Web of Science ®Google Scholar
• Dubrey S, Mendes L, Skinner M, et al. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med. 1996 Sep 15;125(6):481–484.
   PubMed Web of Science ®Google Scholar
• Ayoub K, Vallurupalli S STEMI in a patient with severe thrombocytopenia. Jan. 31, 2017. [cited 2017 Feb 19]. Available from: http://www.acc.org/education-and-meetings/patient-case-quizzes/stemi-in-a-patient-with-severe-thrombocytopenia.
   Google Scholar
• Snowden JA, Greenfield DM, Bird JM, et al. UK myeloma forum (UKMF) and the British Society for Haematology (BSH). Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Br J Haematol. 2017 Mar;176(6):888–907.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. American college of cardiology foundation/American heart association task force on practice guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240–327.
   PubMed Web of Science ®Google Scholar
• Goldsmith YB, Liu J, Chou J, et al. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol. 2009 Oct 1;104(7):990–994.
   PubMed Web of Science ®Google Scholar
• Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2015 Jun;26(6):1091–1101.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 Mar 26;125(13):2068–2074.
   PubMed Web of Science ®Google Scholar